Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...

Shares of Gilead Sciences Inc. GILD slid 2.81% to $103.17 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.74% to 5,525.21 and ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

The Michigan Court of Appeals, in effect, ruled that Chelsea Hospital and the drugmaker, Gilead Sciences Inc., are immune from legal penalties for the contaminated medicine due to a federal law ...

About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company ...

Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $115.28, implying a 10.0% upside ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after ...

Shares of Gilead Sciences Inc. GILD slid 3.66% to $101.40 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 3.46% to ...